HC Wainwright Estimates Ocugen’s Q1 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Ocugen in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their previous forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.21 EPS.

Separately, Chardan Capital lifted their price target on Ocugen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th.

Ocugen Stock Down 1.8 %

NASDAQ:OCGN opened at $0.55 on Monday. The company has a market capitalization of $159.61 million, a price-to-earnings ratio of -3.04 and a beta of 3.88. Ocugen has a one year low of $0.52 and a one year high of $2.11. The stock has a 50-day simple moving average of $0.72 and a 200 day simple moving average of $0.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. During the same period last year, the firm earned ($0.03) earnings per share.

Hedge Funds Weigh In On Ocugen

A number of hedge funds and other institutional investors have recently bought and sold shares of OCGN. BNP Paribas Financial Markets acquired a new position in Ocugen in the fourth quarter valued at approximately $30,000. Ameriprise Financial Inc. acquired a new position in Ocugen in the fourth quarter valued at approximately $30,000. Virtu Financial LLC acquired a new position in Ocugen in the fourth quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its stake in Ocugen by 309.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock valued at $32,000 after acquiring an additional 30,120 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Ocugen in the fourth quarter valued at approximately $40,000. 10.27% of the stock is currently owned by institutional investors and hedge funds.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.